Rosetta Genomics Posts Higher R&D Costs, Widened Loss in Q2; Inks Co-Development Pact with Ben Gurion University | GenomeWeb
NEW YORK (GenomeWeb News) - Rosetta Genomics today reported no second-quarter revenues, accompanied by a 55 percent rise in R&D spending and a 27 percent increase in net loss.
 
R&D spending for the three months ended June 30 increased to $1.7 million from $1.1 million in the year-ago period.
 
Net loss increased to $2.3 million from $1.8 million in the second quarter of 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.